Olfactory Ensheathing Cells In Parkinson'S Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
Olfactory ensheathing cells (OECs) are specialized glial cells in the olfactory system that guide olfactory neuron regeneration. Their dysfunction may contribute to olfactory impairment in Parkinson's disease and represent potential therapeutic targets.
[^2]
[^3]
| Taxonomy |
ID |
Name / Label |
| Cell Ontology (CL) |
CL:0011028 |
olfactory ensheathing cell |
| Database |
ID |
Name |
Confidence |
| Cell Ontology |
CL:0011028 |
olfactory ensheathing cell |
Exact |
| Cell Ontology |
CL:4301615 |
olfactory ensheathing cell (Mmus) |
Exact |
- Axon guidance for olfactory receptor neurons
- Myelin formation in olfactory nerve
- Olfactory bulb support cells
- Regeneration support capacity
- Hybrid astrocyte-Schwann cell phenotype
- Continuous regeneration support
- Blood-nerve barrier maintenance
- Alpha-synuclein accumulation
- Impaired phagocytosis
- Reduced regenerative capacity
- Inflammatory response alterations
- Olfactory restoration potential
- Therapeutic target for hyposmia
- Cell transplantation candidate
- OEC transplantation in PD models
- Functional recovery reports
- Dopaminergic neuron survival enhancement
- Limited availability
- Variable efficacy
- Optimal delivery methods
Olfactory ensheathing cells (OECs) are implicated in Parkinson's disease through several molecular pathways:
- OECs can phagocytose alpha-synuclein aggregates but show impaired clearance in PD
- Accumulation of alpha-synuclein in OECs contributes to olfactory dysfunction
- Lewy body-like inclusions found in olfactory mucosa OECs of PD patients
- OECs produce pro-inflammatory cytokines including TNF, IL1B, and IL6
- Chronic neuroinflammation reduces OEC regenerative capacity
- Altered TGF-beta signaling in PD OECs
- Impaired mitochondrial function in PD OECs
- Reduced PINK1 and PARK2 expression affects OEC survival
- Oxidative stress sensitivity in olfactory ensheathing cells
- Reduced BDNF secretion in PD OECs
- Impaired GDNF signaling affects dopaminergic neuron support
- Altered NTRK2 receptor expression
¶ Key Genes and Proteins
| Gene/Protein |
Function in OECs |
Disease Relevance |
| SNCA |
Alpha-synuclein aggregation |
PD hallmark pathology |
| PINK1 |
Mitochondrial quality control |
Early-onset PD |
| PARK2 |
Ubiquitin-proteasome system |
Juvenile PD |
| GBA |
Lysosomal function |
PD risk factor |
| BDNF |
Neurotrophic support |
Neuronal survival |
| GDNF |
Dopaminergic protection |
Therapeutic target |
| TNF |
Pro-inflammatory cytokine |
Neuroinflammation |
| IL1B |
Inflammatory mediator |
Chronic inflammation |
| TGF-beta |
Immunomodulation |
OEC function |
| NGF |
Neuronal differentiation |
Regeneration |
- Neuroinflammation signaling — chronic activation in PD
- Mitochondrial dysfunction pathway — energy metabolism deficits
- Oxidative stress response — ROS accumulation
- Alpha-synuclein aggregation pathway — protein aggregation
- Neurotrophic factor signaling — BDNF/GDNF pathways
- Autophagy-lysosomal pathway — protein clearance
- Wnt/beta-catenin signaling — regeneration
- TGF-beta signaling — immunomodulation
- Parkinson's Disease — primary disease of interest
- Idiopathic Parkinson's Disease — sporadic PD
- LRRK2-associated Parkinson's Disease — genetic PD form
- Dementia with Lewy Bodies — alpha-synuclein pathology
- Multiple System Atrophy — oligodendroglial pathology
- Progressive Supranuclear Palsy — tau pathology
- Alzheimer's Disease — olfactory dysfunction
- Hyposmia — olfactory loss in PD
- Anosmia — complete smell loss
- REM Sleep Behavior Disorder — PD prodrome
- OEC transplantation to replace damaged olfactory neurons
- Gene therapy to enhance GDNF/BDNF expression in OECs
- Cell-based delivery of therapeutic proteins to brain regions
- Combination approaches with neurotrophic factors
- Anti-inflammatory agents to modulate OEC function
- Antioxidant treatment to reduce oxidative stress
- Mitochondrial protectants to improve OEC survival
- Alpha-synuclein clearance via enhanced autophagy
- Olfactory training combined with OEC activation
- Smell function restoration through OEC regeneration
- Neurotrophic factor delivery for dopaminergic protection
- iPSC-derived OECs for autologous transplantation
- Bioengineered OEC scaffolds for targeted delivery
- CRISPR-based gene editing to correct PD mutations
- Exosome therapy from engineered OECs
The study of Olfactory Ensheathing Cells In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.